Diagnosis and Management of Neurogenic Bladder Dysfunction

Jehad Nabeel Qutub^1, , Mohammed Ahmed Alamoudi¹, Amr Ibrahim Serage¹, Ahmed Awad Mobaraki¹, ‏Mohammed Siraj Alghamdi¹ and Abdulrahman Ali Alamri²

¹Mbbs, Urology Resident, king Fahad Hospital, Jeddah, KSA

²Urology resident, Prince Sultan military medical city, Riyadh, KSA

Cite this paper:
Jehad Nabeel Qutub, Mohammed Ahmed Alamoudi, Amr Ibrahim Serage, Ahmed Awad Mobaraki, ‏Mohammed Siraj Alghamdi and Abdulrahman Ali Alamri. Diagnosis and Management of Neurogenic Bladder Dysfunction. American Journal of Medical Sciences and Medicine. 2020; 8(4):157-163. doi: 10.12691/ajmsm-8-4-4

Abstract

Background: The function of the LUT is mainly storage and voiding of urine, which is regulated by the nervous system that coordinates the activity of the urinary bladder and bladder outlet. The part of the nervous system that regulates LUT function is disseminated from the peripheral nerves in the pelvis to highly specialized cortical areas. Any disturbance of the nervous system involved, can result in neuro-urological symptoms [1]. Methods: this article was done after retrospective longitudinal and observational study including patients with neurogenic bladder and reviewing national and international recent and related literatures to overview neurogenic bladder and most advanced medical and surgical diagnostic procedures and treatment modalities of neurogenic bladder. Results: Among patients included, 52% had an early referral. The majority were diagnosed as neurogenic bladder with high bladder pressure and low bladder compliance and were treated with oxybutynin and intermittent catheterization. Urodynamic follow-up results showed 68% of improvement at the second urodynamic examination decreasing bladder pressure and increasing bladder capacity and compliance. The percentage of incontinence and urinary tract infections decreased over treatment. Conclusion: Multiple conservative modalities, i.e pharmacologic agents, medical devices and neuro modulation, should be promoted before undertaking surgical interventions. Intermittent catheterization and drug therapy are usually sufficient for maintaining continence and preserving upper tracts. Surgical procedures should be considered if conservative measures fail to achieve continence between catheterizations or preserve upper tracts. However today the improvement of Quality of life is the final goal.

Keywords:
neurogenic bladder neurogenic lower urinary tract dysfunction neurogenic bladder surgical management urinary incontinence. urinary retention voiding dysfunction

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Nosseir, M., et al. Clinical usefulness of urodynamic assessment for maintenance of bladder function in patients with spinal cord injury. Neurourol Urodyn, 2007. 26: 228.
[2]	A. J. Wein, “Lower urinary tract dysfunction in neurologicinjury and disease,” in Campbell-Walsh Urology, A. J. Wein, L.R. Kavoussi, A. C. Novick, A. W. Partin, and C. A. Peters, Eds., pp. Saunders, New York, NY, USA, 9th edition, 2007.
[3]	M. O’Leary and M. Dierich, “Botulinum toxin type A forthe treatment of urinary tract dysfunction in neurologicaldisorders,” Urologic Nursing, vol. 30, no. 4, pp. 228-234, 2010.
[4]	Verhoef, M. Lurvink, H. A. Barf et al., “High prevalenceof incontinence among young adults with spina bifida:description, prediction and problem perception,” Spinal Cord,vol. 43, no. 6, pp. 331-340, 2005.
[5]	Wyndaele J, Kovindha A, Madersbacher H, et al. Neurologic urinary and faecal incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence, 4th edn. Paris: Health Publication Ltd, 2009; 912-16.
[6]	Manack, S. P. Motsko, C. Haag-Molkenteller et al., “Epi-demiology and healthcare utilization of neurogenic bladderpatients in a US claims database,” Neurourology and Urody-namics, vol. 30, no. 3, pp. 395-401, 2011
[7]	de Seze M, Ruffi on A, Denys P, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis 2007; 13: 915-28.
[8]	Panicker J, Nagaraja D, Kovoor J, et al. Lower urinary tract dysfunction in acute disseminated encephalomyelitis. Multiple Sclerosis 2009; 15: 1118-22.
[9]	Ruffi on A, de Seze M, Denys P, et al. Groupe d’Etudes de Neuro-Urologie de Langue Francaise (GENULF) guidelines for the management of spinal cord injury and spina bifi da patients. Prog Urol 2007;17:631-3.
[10]	Cameron, A.P., et al. The Severity of Bowel Dysfunction in Patients with Neurogenic Bladder. J Urol, 2015.
[11]	Vodušek, D.B. Lower urinary tract and sexual dysfunction in neurological patients. Eur Neurol, 2014. 72: 109.
[12]	Na, H.R., et al. Urinary incontinence in Alzheimer’s disease is associated with Clinical Dementia Rating-Sum of Boxes and Barthel Activities of Daily Living. Asia Pac Psychiatry, 2015. 7: 113.
[13]	Papatsoris, A.G., et al. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn, 2008. 27: 22.
[14]	Kim, M., et al. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson’s disease. Parkinsonism Relat Disord, 2015. 21: 205.
[15]	Bacsu, C.D., et al. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int, 2012. 109. Suppl 3: 31.
[16]	Wyndaele J-J. Conservative treatment of patients with neurogenic bladder. Eur Urol Suppl. 2008; 7: 557-565.
[17]	Tiryaki, S., Yagmur, I., Parlar, Y., et al (2015). Botulinum injection is useless on fibrotic neuropathic bladders. J Pediatr Urol; 11: 27.
[18]	Kennelly MJ, DeVoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008; 10: 182-191.
[19]	Lehtoranta K, Tainio H, Lukkari-Lax E, et al. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand J Urol Nephrol. 2002; 36: 18-24.
[20]	Bennett N, O’Leary M, Patel AS, et al. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004; 171(2, pt 1): 749-751.
[21]	Madhuvrata P, Sing M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012; 62(5): 816-830.
[22]	Lawrenson, R., Wyndaele, J.J., Vlachonikolis, I., Farmer, C., Glickman, S (2001). Renal failure in patients with neurogenic lower urinary tract dysfunction. Neuroepidemiology. 20(2): 138-143.
[23]	Peters KM, Kandagatia P, Killinger KA, et al. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013; 81: 738-743.
[24]	Gurocak S, Nuininga J, Ure I, et al. Bladder augmentation: review of the literature and recent advances. Indian J Urol. 2007; 23: 452-457.
[25]	Lai, H.H.; Hsu, E.I.; The, B.S.; Butler, E.B.; Boone, T.B. 13 years of experience with artificial urinary sphincter implantation at Baylor College of Medicine. J. Urol. 2007, 177, 1021-1025.
[26]	McFarlane JP, Foley SJ, Shah PJ. Balloon dilatation of the external urethral sphincter in the treatment of detrusor-sphincter dyssynergia. Spinal Cord. 1997; 35: 96-8.
[27]	Boone TB. External urethral sphincter stent for dyssynergia. J Urol. 2009; 181: 1538-9.
[28]	Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005; 76: 1670-6.
[29]	Neuhuber, B.; Barshinger, A.L.; Paul, C.; Shumsky, J.S.; Mitsui, T.; Fischer, I. Stem cell delivery by lumbar puncture as a therapeutic alternative to direct injection into injured spinal cord. J. Neurosurg. Spine 2008, 9, 390-399.
[30]	Jia, C.; Yoshimura, N.; Liao, L. Herpes simplex virus vector-mediated gene transfer of kynurenine aminotransferase improves detrusor overactivity in spinal cord-injured rats. Gene Ther. 2014, 21, 484-489.
[31]	Wein AJ. Classification of neurogenic voiding dysfunction. J Urol. 1981; 125: 605-9.
[32]	Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
[33]	Panicker, J.N., et al. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol, 2015. 14: 720.
[34]	Wyndaele JJ. Complications of intermittent catheterization: their prevention and treatment. Spinal Cord. 2002; 40: 536-541.
[35]	Stohrer M, Blok B, Castro-Diaz D, et al. European Association of Urology guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; 56: 81-8.
[36]	Ab, E. et al. (2014). ‘Detrusor overactivity in spina bifida: how long does it need to be treated?’, Neurourology and urodynamics. United States, 23(7), pp. 685-688.